UnknownNot Applicable

Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA)

50 participantsStarted 2018-11-01

Plain-language summary

To study the in vivo expression of dopamine D2 receptors in nonfunctioning pituitary adenoma and the predictive role of dopamine dopamine D2 receptors PET-MR imaging in the therapeutic effect of dopamine agonists（DA）.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Normal serum pituitary hormone levels or mild increase of serum prolactin.
✓. Enhanced MRI shows a pituitary tumor and tumor diameter\>1cm.
✓. Aged between 18 and 65 years old, either sex.
✓. Karnofsky performance status ≥ 70.
✓. The patient has signed the informed consent.

Exclusion criteria

✕. Patients concomitantly taking the psychotropic drugs.
✕. Patients with parkinson disease and is taking dopaminergic agents.
✕. Patients with pituitary adenoma who received Gamma knife treatment.
✕. Pregnant or lactating women.
✕. Patients with poor compliance, who cannot implement the program strictly.
✕. History of allergic reactions attributed to compounds of similar chemical or biologic composition to cabergoline.
✕. Patients with claustrophobia. -

What they're measuring

Change from baseline on tumor volume

Timeframe: Up to 6 months]

Trial details

NCT IDNCT03714763

SponsorZhebao Wu

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-11-30

Contact for this trial

Weiting Gu, MD

0086-13917778956 nowaiting1221@hotmail.com

View on ClinicalTrials.gov More Pituitary Adenoma trials